Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2010 Jul;19(7):909-11.
doi: 10.1517/13543784.2010.489547.

Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?

Sabina A Antoniu  1
Affiliations
Comment

Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?

Sabina A Antoniu. Expert Opin Investig Drugs. 2010 Jul.

Abstract

Importance of the field: Inhalational anthrax is a disease with a high lethality potential and current therapeutic interventions with antibiotics to manage the bacteraemia might not always be fully effective. Blocking the activity of the toxins with raxibacumab, a fully-human mAb directed against the protective antigen of Bacillus anthracis, may serve as an adjunct treatment. The existing ones are aimed at preventing post-exposure bacteraemia but might not be always fully protective. Therefore, more specific 'therapies' are needed and the protective antigen of B. anthracis might be targeted effectively with raxibacumab, which is a blocking human mAb. AREAS COVERED IN THIS PAPER: To discuss the results of experimental and human studies evaluating raxibacumab for inhalational anthrax.

What the reader will gain: Raxibacumab was efficacious prophylactically after exposure and therapeutically before exposure in rabbit and monkey animal models of inhalational anthrax and exhibited good safety and pharmacokinetic profiles in healthy humans.

Take home message: Raxibacumab is a promising prophylactic and therapeutic for inhalational anthrax.

PubMed Disclaimer

Comment on

  • Raxibacumab for the treatment of inhalational anthrax.
    Migone TS, Subramanian GM, Zhong J, Healey LM, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, Bolmer SD. Migone TS, et al. N Engl J Med. 2009 Jul 9;361(2):135-44. doi: 10.1056/NEJMoa0810603. N Engl J Med. 2009. PMID: 19587338 Clinical Trial.

MeSH terms

LinkOut - more resources